SHILPA MEDICARE LTD.

Shilpa Medicare Ltd has announced that its Board of Directors will convene on November 5, 2026. The primary agenda item is to consider and approve the unaudited financial results for the second quarter and half-year ended September 30, 2026, covering both consolidated and standalone figures. Additionally, the company has informed about the closure of its trading window from October 1, 2026, to November 7, 2026, in compliance with its insider trading code.

Shilpa Medicare Limited's Unit 4 in Jadcherla, Telangana, has received GMP Certification from AGES, Austria, following a successful inspection. This unit is crucial for manufacturing, testing, and distributing sterile injections and non-sterile tablets and capsules for European and global markets. The approval signifies adherence to stringent European quality standards, potentially boosting export capabilities and market access.

Shilpa Medicare Ltd announced the release of encumbrance on 30,00,000 equity shares, representing 1.5337% of the company's paid-up share capital. This action was taken by members of the Promoter Group, including Vishnukant C Bhutada, Dharmavati Bhutada, Deepak Kumar Innani, Ramakant Innani, Om Prakash Inani, and Brijgopal Innani. The encumbrance, which was in the form of a pledge, was released on September 25, 2026, primarily for loans taken by the promoters. This move signifies a reduction in pledged shares by the promoter group.

Shilpa Medicare Ltd has announced the closure of its trading window for designated persons and their immediate relatives, as well as connected persons, effective October 1, 2026. This closure will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ended September 30, 2026. The company has advised all designated persons against trading in its securities during this period. The specific date for the board meeting to consider these financial results will be communicated later.

Shilpa Medicare Ltd has been assigned an Environmental, Social and Governance (ESG) score of "Crisil ESG 59" by CRISIL ESG Ratings & Analytics Limited. The score is based on disclosures for fiscal 2026 and publicly available data. Notably, the company did not engage CRISIL ESG Ratings for this assessment, as it was independently prepared by CRISIL based on public domain information. This disclosure is made in compliance with SEBI regulations.

Shilpa Medicare Limited announced that its Unit VII, Analytical Services Division in Hyderabad underwent a USFDA Surveillance Inspection from September 16-18, 2026. The inspection concluded with a single procedural observation, which was not a repeat and did not relate to data integrity. The company plans to address this observation and submit a response within the stipulated timeline. Shilpa Medicare expects no material impact on its current business operations or supplies from this facility.

Shilpa Medicare Limited has received final approval from the Subject Expert Committee (SEC) under CDSCO for marketing authorization of OERIS™ (Ondansetron Extended-Release Injection, 100 mg/mL). This novel complex injectable is the world's first extended-release ondansetron injectable formulation, offering sustained antiemetic action for up to 120 hours (5 days) after a single dose. The approval is based on successful Phase III trials for chemotherapy-induced nausea and vomiting (CINV). The company plans to launch OERIS™ in India, where it has patent protection until 2039. This development is expected to enhance patient convenience and healthcare efficiency, further strengthening Shilpa Medicare's oncology portfolio.

Shilpa Medicare Limited announced that its wholly-owned subsidiary, FTF Pharma Private Limited, has been admitted to Corporate Insolvency Resolution Process (CIRP) by the National Company Law Tribunal (NCLT), Ahmedabad Bench. The order, dated September 9, 2026, was passed following an application by Immacule Lifesciences Private Limited under Section 9 of the Insolvency and Bankruptcy Code, 2016, citing an alleged operational debt of ₹2,18,03,319. The NCLT found the debt valid and ordered a moratorium. Shilpa Medicare is consulting legal advisors to assess the situation and future actions, with further updates to be provided as developments occur. The impact on the parent company's financials and operations is currently not quantifiable.

Shilpa Medicare Ltd has dispatched a letter to shareholders whose email addresses are not registered, providing the web-link to the Annual Report for FY 2025-26 and the Notice for the 39th Annual General Meeting (AGM). The AGM will be held on September 11, 2026, via Video Conferencing. The notice and annual report are available on the company's website. The cut-off date for voting eligibility is September 4, 2026, with remote e-voting commencing on September 7 and concluding on September 10, 2026.

Shilpa Medicare Ltd has voluntarily recalled over 27,923 vials of its Pemetrexed Injection in the United States due to atypical discoloration. The recall, initiated on July 29, 2026, covers four batches of the chemotherapy drug. The US FDA has classified this as a Class II recall. The company stated that no adverse events have been reported and does not anticipate any material impact on its financial position or operations. This disclosure is made in response to a news report published on August 17, 2026.